Verve Therapeutics, on the march toward the clinic with a next-gen heart drug, wants a piece of the ever-growing biotech IPO pie.

Novartis has signed up to a collab pact and possible buyout deal, should all go to plan, for quiet, little-known Swiss biotech Cellerys.

HCW Biologics has filed to raise up to $50 million in an IPO. The money will set HCW up to take two immunotherapy treatments into the clinic in solid tumors and an autoimmune disorder.

Provention was flying high on Tuesday when an FDA advisory panel seemed to back the efficacy of its diabetes prevention drug, even after the agency flagged some issues with the data package supporting the therapy’s application a month earlier. But the company is not out of the woods yet, with the final vote only narrowly supporting the drug’s approval Thursday afternoon.

The Securities and Exchange Commission (SEC) settled insider trading charges against one of Karuna Therapeutics’ investors, a doctor and medical investigator who bought more than 1,600 shares after hearing secret details from a positive clinical trial readout.

Scientia Vascular may focus largely on producing medical devices of tiny proportions, but that certainly doesn’t carry over to its latest wave of financing.

Tectonic Therapeutic has appointed Peter McNamara, Ph.D., as head of research. McNamara joins Tectonic from the Genomics Institute of the Novartis Research Foundation (GNF), where he rose to the title of head of biotherapeutics and biotechnology over a 16-year spell at the group.

In a vote of confidence for anyone who’s ever insisted on using the internet to diagnose their own illness before even scheduling a doctor’s appointment, Ada Health has raked in a sizable series B to continue growing its symptom-checking platform.

Esco Lifesciences has raised $200 million in a series A and crossover round co-led by Novo Holdings and Vivo Capital. The Singapore-based company will use the cash to establish a hub for cell and gene therapy tools and technologies in Boston while expanding in China and making bolt-on acquisitions.

Pulmocide, targeting serious acute and chronic respiratory diseases, today breathed in an oversubscribed $92 series C as an IPO looks to be on the cards.